Advanced Adult Primary Liver Cancer Clinical Trial
Official title:
A Phase 2 Study of IMC-A12 (NSC742460) in Hepatocellular Carcinoma
This phase II trial is studying how well IMC-A12 works in treating patients with advanced liver cancer. Monoclonal antibodies, such as IMC-A12, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them.
Status | Completed |
Enrollment | 24 |
Est. completion date | February 2011 |
Est. primary completion date | February 2011 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Histologically or cytologically confirmed hepatocellular carcinoma - Unresectable, locally advanced, or metastatic disease - Measurable disease, defined as = 1 unidimensionally measurable lesion = 20 mm by conventional techniques OR = 10 mm by spiral CT scan - Child's Pugh score A5, A6, B7, or B8 - No known brain metastases - No history of primary CNS tumors - ECOG performance status (PS) 0-2 OR Karnofsky PS 60-100% - Life expectancy > 3 months - Leukocytes = 3,000/mcL - Absolute neutrophil count = 1,500/mcL - Platelet count = 75,000/mcL - Total bilirubin = 2 times upper limit of normal (ULN) - AST/ALT = 2.5 times ULN - PT/INR = 1.7 times ULN - Creatinine = 1.5 mg/dL OR creatinine clearance = 60 mL/min - Fasting serum glucose = 125 mg/dL - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - No clinical encephalopathy - No history of allergic reactions attributed to compounds of similar chemical or biologic composition to anti-IGF-1R recombinant monoclonal antibody IMC-A12 - No poorly controlled diabetes mellitus - Patients with a history of diabetes mellitus are eligible provided their blood glucose is within normal range (fasting blood glucose < 120 mg/dL OR below ULN) and patient is on a stable dietary or therapeutic regimen for this condition - No concurrent uncontrolled illness including, but not limited to, any of the following: - Ongoing or active infection - Symptomatic congestive heart failure - Unstable angina pectoris - Cardiac arrhythmia - Psychiatric illness or social situation that would preclude compliance with study requirements - No history of seizures not well controlled with standard medical therapy - No history of stroke - No history of another primary cancer except for the following: - Curatively resected nonmelanoma skin cancer - Curatively treated carcinoma in situ of the cervix - Other primary solid tumor with no known active disease present that in the opinion of the investigator would not affect treatment outcome - Prior local therapy (i.e., surgery, radiotherapy, hepatic arterial embolization, radiofrequency ablation, percutaneous ethanol injection, or cryoablation) allowed provided the target lesion has not been treated with local therapy and/or the target lesion within the field of local therapy has shown an increase of = 25% in size - At least 4 weeks since prior local therapy - No prior systemic therapy except for sorafenib tosylate - No prior agents targeting the IGF or IGF-1R pathway - No concurrent combination antiretroviral therapy for HIV-positive patients - No other concurrent investigational agents - No concurrent anticancer therapy |
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Memorial Sloan-Kettering Cancer Center | New York | New York |
Lead Sponsor | Collaborator |
---|---|
National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | PFS Rate | PFS defined as the time from first date of first treatment on the study until such time as progressive disease is confirmed or upon patient death if disease progression has not been evident at that time. A Simon's optimal two stage design will be used with the following assumption: a 4 months PFS of 62% is considered acceptable while a 4 months PFS of 42% is not acceptable. | At 4 months | No |
Primary | Best Overall Response Rate (ORR) | Best overall ORR will be defined as the proportion of patients achieving either confirmed partial response (PR) or confirmed complete response (CR). A Simon's optimal two stage design will be used with the following assumption: ORR of more than 20% is acceptable and an ORR less than 5% is not acceptable. | From the start of the treatment until disease progression/recurrence | No |
Secondary | Median Overall Survival | Median Overall Survival | Post-Treatment | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00787787 -
Sunitinib Malate and Capecitabine in Treating Patients With Unresectable or Metastatic Liver Cancer
|
Phase 2 | |
Completed |
NCT00052364 -
Oxaliplatin in Treating Patients With Liver Cancer
|
Phase 2 | |
Completed |
NCT01229111 -
Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary Cancers
|
Phase 2 | |
Completed |
NCT00107536 -
Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer
|
Phase 2 | |
Completed |
NCT02072356 -
Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot be Removed by Surgery
|
Early Phase 1 | |
Completed |
NCT00604721 -
Selumetinib in Treating Patients With Locally Advanced or Metastatic Liver Cancer
|
Phase 2 | |
Completed |
NCT00101036 -
Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery
|
Phase 2 | |
Completed |
NCT00028496 -
Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer
|
Phase 1 | |
Completed |
NCT01766219 -
CPI-613 in Treating Patients With Advanced or Metastatic Bile Duct Cancer That Cannot Be Removed By Surgery
|
Phase 1/Phase 2 | |
Terminated |
NCT00427973 -
AZD2171 in Treating Patients With Locally Advanced Unresectable or Metastatic Liver Cancer
|
Phase 2 | |
Completed |
NCT00321594 -
Belinostat in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
|
Phase 1/Phase 2 | |
Terminated |
NCT00087191 -
EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer
|
N/A | |
Completed |
NCT00006016 -
Thalidomide and Chemoembolization With Doxorubicin in Treating Patients With Liver Cancer That Cannot be Removed by Surgery
|
Phase 2 | |
Completed |
NCT01643499 -
Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies
|
Phase 1 | |
Completed |
NCT00083226 -
Doxorubicin and Bortezomib in Treating Patients With Liver Cancer
|
Phase 2 | |
Completed |
NCT00033462 -
Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer
|
Phase 2 | |
Completed |
NCT01666756 -
Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer
|
Phase 1 | |
Active, not recruiting |
NCT02119065 -
Pilot Study to Assess Lung Shunting of Yttrium-90 Microspheres Using PET/CT
|
||
Recruiting |
NCT02557503 -
Hepatic Arterial Infusion of Oxaliplatin and Fluorouracil Treatment of Advanced Primary Liver Cancer After TACE
|
Phase 4 | |
Withdrawn |
NCT01859182 -
Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By Surgery
|
Phase 2 |